HSC Exam Practice

Sample response. A stakeholder is any person or group affected by a biotechnology, including those who develop, regulate, use or are affected by it. Examples include farmers, consumers, patients, biotechnology companies, government regulators, environmental groups, and (in animal biotechnology) the modified animals themselves.

Marking notes. 1 mark for a correct definition (any group affected by the biotechnology, not only scientists or companies); 1 mark for two valid distinct examples.

Sample response. (1) Welfare — the suffering or stress imposed on humans, animals or communities by the biotechnology. (2) Ownership / patents — who controls the technology, the seed or genetic material, and the resulting power imbalance. (3) Equity — fairness in the distribution of benefits and risks across stakeholder groups. (Other accepted criteria: environmental impact / biodiversity, consent, social or cultural implications.)

Marking notes. 1 mark per correctly named and briefly explained criterion, max 3. Naming alone (without a one-line explanation) earns half a mark, rounded down.

Sample response. Plant biotechnology most directly raises issues of food security, seed ownership and patent dependence, agricultural biodiversity, and ecological effects beyond the target crop. Animal biotechnology raises those issues as well, but additionally raises sharper welfare concerns because the modified organism is sentient and can experience suffering, stress, deformity or confinement. The welfare criterion is therefore engaged more directly in animal biotechnology than in plant biotechnology.

Marking notes. 1 mark for naming plant-specific concerns (food security / ownership / environment); 1 mark for naming animal-specific concerns (welfare, suffering); 1 mark for explicitly stating that welfare is engaged more directly in animals because the modified organism is sentient.

Sample response. Productivity is one criterion in ethical evaluation but not the only one. A biotechnology may increase yield or medical output and still fail other criteria: it may impose welfare costs on animals or workers, concentrate ownership in a few patent-holders and create dependence, distribute benefits inequitably across rich and poor stakeholders, or harm the wider environment through gene flow or biodiversity loss. Ethical justification requires the productivity benefit to be weighed against welfare, ownership, equity and environmental effect, not treated as an automatic override.

Marking notes. 1 mark for stating that productivity is one criterion among several; 1 mark for naming at least two additional criteria that must also be satisfied; 1 mark for explaining that ethical justification requires weighing benefit against these other criteria (rather than treating productivity as an override).

Sample response. Patented seed systems typically prohibit farmers from saving and replanting harvested seed, forcing them to repurchase patented seed every season. This creates economic dependence on the patent-holding company and reduces farmer choice. The most directly affected stakeholder group is farmers, especially smallholders in low-income regions for whom the recurring cost is a serious barrier.

Marking notes. 1 mark for a correct concern (dependence / no seed-saving / reduced farmer choice / concentration of corporate control); 1 mark for naming the stakeholder group (farmers / smallholders).

Sample response. Different stakeholder groups prioritise different values and experience the biotechnology differently. Farmers may prioritise yield and economic security; consumers may prioritise affordability, safety and transparency; companies may prioritise innovation, profit and patent control; regulators may prioritise public safety and trust; environmental groups may prioritise biodiversity and ecological sustainability. Because each group weighs benefit and harm against different criteria, the same biotechnology can be acceptable to one group and unacceptable to another — which is precisely why stakeholder analysis, rather than a single perspective, is required for sound ethical evaluation.

Marking notes. 1 mark for identifying that different groups prioritise different values; 1 mark for at least two distinct examples of group + value pairings; 1 mark for explicitly linking the disagreement to the need for stakeholder analysis (not a single viewpoint).

Sample response. The editorial commits two central ethical errors. First, it conflates technical success with ethical acceptability — the central misconception the framework warns against. The CRISPR edit may have worked at the molecular level, but ethical evaluation must also consider welfare (long-term off-target effects unknown), consent (the future children could not consent, and parental informed consent appears to have been incomplete), oversight (the work bypassed regulatory and ethics-committee approval) and equity (heritable editing could entrench biological inequality if access remains limited to wealthy families). Second, dismissing opposition as "emotional resistance" mischaracterises the framework. Concerns about heritable risk, lack of consent from future generations and inadequate oversight are not emotional reactions — they are systematic applications of welfare, consent and equity criteria, exactly the criteria the framework lists. The correct ethical position is that, even when an editing technique works, its acceptability depends on whether the stakeholder analysis (parents, future children, future generations, regulators, society) supports the intervention, and whether welfare, consent, equity and oversight have all been satisfied. The 2018 case failed on consent, oversight and equity grounds regardless of the technical outcome.

Marking notes. 1 mark for identifying the "technical success = ethical advance" conflation; 1 mark for naming consent as a violated criterion (future children / inadequate informed consent); 1 mark for naming welfare or unknown long-term risk; 1 mark for naming the bypass of regulatory / ethics oversight; 1 mark for naming equity or social-implication risk (e.g. potential to entrench biological inequality); 1 mark for reaching an explicit evaluative judgement framed as stakeholder analysis rather than as anti-progress.

Sample response. The claim that food-security or medical-benefit improvements determine ethical acceptability oversimplifies ethical evaluation. While these benefits are important criteria, the framework requires they be weighed against welfare, ownership, equity and environmental effect, across multiple stakeholder groups, before any judgement is reached. Consider a plant example: Golden Rice is a GM cultivar engineered to express β-carotene in the endosperm, targeting Vitamin A deficiency in low-income regions. Its food-security and medical benefits are real (WHO estimates 250,000–500,000 children blinded yearly by Vitamin A deficiency), and royalty-free licensing to public-sector breeders addresses the standard ownership concern. However, ethical evaluation must still consider ecological risk (gene flow into wild rice relatives), agricultural biodiversity (whether Golden Rice displaces traditional cultivars), and farmer autonomy (whether communities consent to adoption). The benefit alone does not settle the question. Consider an animal example: recombinant bovine somatotropin (rBST), a growth hormone administered to dairy cows to increase milk yield by 11–15%, has been judged biochemically safe for consumers. Yet it is banned in the EU, Canada, Japan, New Zealand and Australia because it raises welfare concerns (associated with higher mastitis, lameness and fertility issues in treated cows) and equity concerns (concentration of patent ownership). Here the productivity benefit is real, but other criteria override it. Comparing the two examples shows that benefit is necessary but not sufficient for ethical acceptability. Plant biotechnology often passes the welfare criterion trivially but engages ownership, biodiversity and equity criteria sharply; animal biotechnology engages welfare directly because the modified organism is sentient. In both domains, stakeholder analysis exposes who benefits, who carries risk, and whether harms are justified — and that analysis can reverse a judgement that looked obvious from benefit alone. The claim is therefore rejected: ethical acceptability is determined by the balance of benefits against welfare, ownership, equity and environmental effect across all relevant stakeholders, not by food security or medical outcomes alone.

Marking notes. 1 mark — states the claim is an oversimplification and identifies benefit as one criterion among several. 1 mark — names a valid plant biotechnology with brief description (e.g. Golden Rice, Bt cotton, Roundup Ready soy). 1 mark — names a valid animal biotechnology with brief description (e.g. rBST dairy cattle, AquAdvantage salmon, OncoMouse, GloFish). 1 mark — applies the welfare criterion to the animal example with specific welfare evidence (e.g. mastitis in rBST cows). 1 mark — applies the ownership / equity criterion to at least one example (e.g. patented seed, royalty-free licensing, market bans). 1 mark — applies the environmental criterion (gene flow, biodiversity, escape risk). 1 mark — explicitly uses stakeholder analysis — who benefits, who carries risk — rather than a single viewpoint. 1 mark — reaches an evaluative judgement that benefit is necessary but not sufficient, and that ethical acceptability is context-dependent across the full criterion set.